ClinicalTrials.gg
RecruitingNCT06190067Updated Jan 30, 2024

Azacitidine Plus PD-1 Therapy for R/R Hodgkin Lymphoma

A Phase 2 interventional study of Azacitidine Plus PD-1 therapy in Relapsed Classic Hodgkin Lymphoma and Refractory Classic Hodgkin Lymphoma, sponsored by Navy General Hospital, Beijing. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-01-30.

Sponsored by Navy General Hospital, Beijing · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2023; still recruiting 3 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 57 studies in Hodgkin Disease with a site in China — 28 open to participants now, 31 under way, 3 of them phase 3. Hodgkin Disease · China.

Planned enrollment
41st of 53
40 · median 75
Started
2023
with 5 others
Phase 2
26 of 57
13 open now
Primary completion
2026-12
later than 19 of 30 live
Registered
44th of 57
by date

Among the 57 studies in Hodgkin Disease with a site in China, this one is the 41st largest by planned enrollment of the 53 interventional ones that give a count, is one of 6 that started in 2023, is one of 26 in phase 2, reaches primary completion later than 19 of the 30 other live ones, and was the 44th registered.

Hodgkin Disease

1,384 studies on the registry are indexed under Hodgkin Disease; 160 are open to participants now.

Browse Hodgkin Disease studies →

Open to participants now

28 of the 57 studies in Hodgkin Disease with a site in China are open now. Recruiting first, the newest first:

22 more — sign in →

All 28 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 133 Hodgkin Disease studies recruiting now, 70 (53%) set no upper age limit and 51 (38%) stop at 75 or younger; 46 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 57 studies in Hodgkin Disease with a site in China, or all of them as a file.
02

Study summary

The goal of this phase 2 trial is to test the safety and efficacy of azacitidine when given together with PD-1 therapy in treating patients with relapsed/refractory classic Hodgkin lymphoma.

Read the detailed description

The investigators will evaluate response rate, progression free survival (PFS), overall survival (OS), and toxicity of azacytidine combined with PD-1 therapy in classic relapsed/refractory Hodgkin lymphoma.

03

Conditions studied

  • Relapsed Classic Hodgkin Lymphoma
  • Refractory Classic Hodgkin Lymphoma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed Hodgkin Lymphoma according World Health Organization (WHO) classification.
  • Patient is ≥ 18 years of age at the time of signing the form (ICF).
  • Patient must understand and voluntarily sign an ICF prior to any study-specific assessments/procedures being conducted.
  • Patient is willing and able to adhere to the study visit schedule and other protocol requirements.
  • (after partial or complete response) or refractory AITL after at least one (there is no mandatory resting period after the previous treatment as long as the biochemistry and hematology labs meet the inclusion criteria as below).
  • Meet the following lab criteria: (ANC) ≥ 1,5 x 10\^9/L (≥ 1 x 10\^9/L if bone marrow (BM) involvement by lymphoma); ≥ 75 x 10\^9/L (≥ 50 x 10\^9/L if BM involvement by lymphoma); ≥ 8 g/dL.
  • Anticipated at least 3 months.

Exclusion criteria

Exclusion Criteria:

  • Active or uncontrolled infections requiring systemic treatment within 14 days before enrollment.
  • Any instability of systemic disease, including but not limited to severe cardiac, liver, kidney, or metabolic disease need therapy.
  • Pregnant or lactating women.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Azacitidine Plus PD-1 therapy

    Patients were treated by Azacitidine plus PD-1 therapy

    Drug: Azacitidine Plus PD-1 therapy

Interventions

  • DrugAzacitidine Plus PD-1 therapy

    Patients were treated by Azacytidine(75 mg/m2 subcutaneous injection qd on days 1-7) plus PD-1 therapy(200mg iv qd d8)

    Also known as: Azacitidine Plus PD-1 antibody

06

What researchers measure

Primary outcomes

  1. Overall Response Rate (ORR)

    ORR was defined as the proportion of patients who achieved CR or PR as their best response

    Time frame: 1 year

Secondary outcomes

  1. Overall Survival (OS)

    OS was defined as time from diagnosis to death from any cause or the last follow-up

    Time frame: through study completion, an average of 2 year

  2. Progression Free Survival (PFS)

    PFS using local assessment of progressive disease according to Lugano Response Criteria (2014)

    Time frame: 18 months

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2023 (actual). Primary completion is estimated for Dec 2026, 38 months after the start.

Of 180 non-industry phase 2 interventional studies under Hodgkin Disease, half reached primary completion within 80 months of starting (the median), counting those still running; a quarter within 48 and three quarters within 115. This study's planned 38 months is below that.

Counting every sponsor, half of 203 studies reached it within 75 months; a quarter within 42 and three quarters within 111.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 19, 2023
First posted
Jan 5, 2024
StartActual
Oct 30, 2023
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2028
Last update
Jan 30, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 30, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06190067
Lead sponsor
Navy General Hospital, Beijing
Responsible party
Liren Qian (Vice Director, Navy General Hospital, Beijing) — Principal investigator
First posted
Jan 5, 2024
Start date
Oct 30, 2023
Primary completion
Dec 2026 (estimated)
Completion
Dec 2028 (estimated)
Last update
Jan 30, 2024

Study contacts

Liren Qian, PhD
Contact
qlr2007@126.com
+861066947192
Liren Qian, PhD
principal investigator · Navy General Hospital, Beijing

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion